Maximizing neuroprotection: where do we stand?

被引:11
|
作者
Kuffler, Damien P. [1 ]
机构
[1] Univ Puerto Rico, Inst Neurobiol, San Juan, PR 00901 USA
来源
THERAPEUTICS AND CLINICAL RISK MANAGEMENT | 2012年 / 8卷
关键词
adenosine; hypothermia; alkalinization; glucocorticoids; SPINAL-CORD-INJURY; RETROGRADE VENOUS PERFUSION; ADENOSINE A(2A) AGONIST; CULTURED HIPPOCAMPAL-NEURONS; CENTRAL-NERVOUS-SYSTEM; RAT SENSORY NEURONS; CELL-DEATH; IN-VITRO; GLUTAMATE NEUROTOXICITY; CEREBRAL-ISCHEMIA;
D O I
10.2147/TCRM.S16196
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Brain and spinal cord traumas include blunt and penetrating trauma, disease, and required surgery. Such traumas trigger events such as inflammation, infiltration of inflammatory and other cells, oxidative stress, acidification, excitotoxicity, ischemia, and the loss of calcium homeostasis, all of which cause neurotoxicity and neuron death. To prevent trauma-induced neurological deficits and death, each of the many neurotoxic events that occur in parallel or sequentially must be minimized or prevented. Although neuroprotective techniques have been developed that block single neurotoxic events, most provide only limited neuroprotection and are only applied singly. However, because many neurotoxicity triggers arise from common events, an approach for invoking more effective neuroprotection is to apply multiple neuroprotective methods simultaneously before the many neurotoxic triggers and cascades are initiated and become irreversible. This paper first discusses some triggers of neurotoxicity and neuroprotective mechanisms that block them, including hypothermia, alkalinization, and the administration of adenosine. It then examines how the simultaneous application of these techniques provides significantly greater neuroprotection than is provided by any technique alone. The paper also stresses the importance of determining whether the neuroprotection provided by these techniques can be further enhanced by combining them with additional techniques, such as the systemic administration of glucocorticoids. Finally, the paper stresses the absolute critical importance of applying these techniques within the "golden hour" following trauma, before the many neurotoxic events and cascades are manifest and before the neurotoxic cascades become irreversible.
引用
收藏
页码:185 / 194
页数:10
相关论文
共 50 条
  • [21] Targeted therapies for small cell lung cancer: Where do we stand?
    Arcaro, Alexandre
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2015, 95 (02) : 154 - 164
  • [22] Radiation Therapy for Meningiomas - Where Do We Stand and What's on the Horizon?
    Ehret, Felix
    El Baya, Leon
    Erridge, Sara C.
    Bussiere, Marc
    Verhoeff, Joost J. C.
    Niyazi, Maximilian
    Preusser, Matthias
    Minniti, Giuseppe
    Shih, Helen A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2025, 121 (03): : 599 - 612
  • [23] Bicuspid aortic valve-associated aortopathy: Where do we stand?
    Messner, Barbara
    Bernhard, David
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2019, 133 : 76 - 85
  • [24] Cannabinoid receptors as therapeutic targets for autoimmune diseases: where do we stand?
    Goncalves, Elaine D.
    Dutra, Rafael C.
    DRUG DISCOVERY TODAY, 2019, 24 (09) : 1845 - 1853
  • [25] Mesenchymal stem cell secretome for regenerative medicine: Where do we stand?
    Trigo, Catarina M.
    Rodrigues, Joana S.
    Camoes, Sergio P.
    Sola, Susana
    Miranda, Joana P.
    JOURNAL OF ADVANCED RESEARCH, 2025, 70 : 103 - 124
  • [26] Reprogramming and transdifferentiation for cardiovascular development and regenerative medicine: where do we stand?
    Ebert, Antje D.
    Diecke, Sebastian
    Chen, Ian Y.
    Wu, Joseph C.
    EMBO MOLECULAR MEDICINE, 2015, 7 (09) : 1090 - 1103
  • [27] The Pivotal Role of Senescence in Cell Death and Aging: Where Do We Stand?
    Mohammad Zeeshan Sadaf
    Vyas Najm
    Moin Shingatgeri
    Mohammad Asrar Uddin
    Md Salman Izhari
    Atul Akhtar
    Subhabrata Kathait
    Ishita Kar
    Pulkit Jain
    Komal Datt
    Anoushka Komal
    Current Molecular Biology Reports, 2020, 6 (2) : 91 - 101
  • [28] Perioperative pain, analgesics and cancer-related outcomes: where do we stand?
    Ramirez, Maria F.
    Rangel, Felipe P.
    Cata, Juan P.
    PAIN MANAGEMENT, 2021, 12 (02) : 229 - 242
  • [29] Cladribine in the remission induction of adult acute myeloid leukemia: where do we stand?
    Qasrawi, Ayman
    Bahaj, Waled
    Qasrawi, Lien
    Abughanimeh, Omar
    Foxworth, John
    Gaur, Rakesh
    ANNALS OF HEMATOLOGY, 2019, 98 (03) : 561 - 579
  • [30] The Role of Carrageenan in Inflammatory Bowel Diseases and Allergic Reactions: Where Do We Stand?
    Borsani, Barbara
    De Santis, Raffaella
    Perico, Veronica
    Penagini, Francesca
    Pendezza, Erica
    Dilillo, Dario
    Bosetti, Alessandra
    Zuccotti, Gian Vincenzo
    D'Auria, Enza
    NUTRIENTS, 2021, 13 (10)